136 related articles for article (PubMed ID: 22039139)
21. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
Eng KH; Morrell K; Starbuck K; Spring-Robinson C; Khan A; Cleason D; Akman L; Zsiros E; Odunsi K; Szender JB
Gynecol Oncol; 2017 Jul; 146(1):52-57. PubMed ID: 28495239
[TBL] [Abstract][Full Text] [Related]
23. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.
Wahner Hendrickson AE; Hawthorne KM; Goode EL; Kalli KR; Goergen KM; Bakkum-Gamez JN; Cliby WA; Keeney GL; Visscher DW; Tarabishy Y; Oberg AL; Hartmann LC; Maurer MJ
Gynecol Oncol; 2015 Apr; 137(1):77-85. PubMed ID: 25620544
[TBL] [Abstract][Full Text] [Related]
24. The impact of geographic variations in treatment on outcomes in ovarian cancer.
Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS
Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939
[TBL] [Abstract][Full Text] [Related]
25. A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer.
Park HJ; Nam EJ; Rha SY; Kim S; Kim SW; Kim JW; Kim YT
Gynecol Oncol; 2012 Sep; 126(3):357-63. PubMed ID: 22687686
[TBL] [Abstract][Full Text] [Related]
26. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
[TBL] [Abstract][Full Text] [Related]
27. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
28. Epithelial ovarian cancer.
Ng JS; Low JJ; Ilancheran A
Best Pract Res Clin Obstet Gynaecol; 2012 Jun; 26(3):337-45. PubMed ID: 22281513
[TBL] [Abstract][Full Text] [Related]
29. Non-surgical management of ovarian cancer: Prevalence and implications.
Shalowitz DI; Epstein AJ; Ko EM; Giuntoli RL
Gynecol Oncol; 2016 Jul; 142(1):30-37. PubMed ID: 27107721
[TBL] [Abstract][Full Text] [Related]
30. Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.
Horng HC; Lai CR; Chang WH; Wen KC; Chen YJ; Juang CM; Yen MS; Wang PH
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):547-51. PubMed ID: 25510699
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
[TBL] [Abstract][Full Text] [Related]
32. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
33. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
34. Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome.
Sijmons EA; van Lankveld MA; Witteveen PO; Peeters PH; Koot VC; van Leeuwen JS
Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):203-8. PubMed ID: 16707204
[TBL] [Abstract][Full Text] [Related]
35. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
[TBL] [Abstract][Full Text] [Related]
36. Early stage mucinous ovarian cancer: A review.
Crane EK; Brown J
Gynecol Oncol; 2018 Jun; 149(3):598-604. PubMed ID: 29429591
[TBL] [Abstract][Full Text] [Related]
37. Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA
Gynecol Oncol; 2018 Oct; 151(1):18-23. PubMed ID: 30135020
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer.
Wei W; Li N; Sun Y; Li B; Xu L; Wu L
Oncotarget; 2017 Apr; 8(14):23862-23870. PubMed ID: 27852043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
